Covidien公布产品组合处理活动--关于出售睡眠疗法产品线的最终协议 完成美国放射性药物产品线的出售

2010-06-02 14:40

• 关于出售睡眠疗法产品线的最终协议
• 完成美国放射性药物产品线的出售

都柏林--(美国商业资讯)--全球领先的健康保健产品供应商Covidien（纽约证券交易所代码：COV）今天公布了一项最终协议，将其睡眠疗法(Sleep Therapy)持续气道正压通气(CPAP)与Bi-level产品线出售给位于卢森堡的未公开上市企业PH Invest。

PH Invest将收购CPAP与Bi-level产品线，包括法国南锡的制造工厂和位于欧洲的相关商业部门。以GoodKnight^TM和Sandman^TM品牌销售的多种产品也包括在该协议中。该协议中不包括以Adam^TM、Breeze^TM和Dreamfit^TM品牌进行销售和营销的睡眠辅助产品，这些产品将继续由Covidien销售。该交易的财务条款未予披露。

这项交易预计将在未来90天内完成，但仍需达成惯例成交条件。该交易预计不会对2010或2011年的经营盈余或每股盈余产生实质性影响。

此外，Covidien之前公布的将其美国的放射性药物产品线出售给位于佛罗里达州奥兰多的Triad Isotopes, Inc.的交易也已完成。该交易的财务条款同样未予披露。

2010会计年上半年，Covidien放射性药物产品线的净销售额为9100万美元。这项交易预计不会对Covidien 2010或2011会计年的经营盈余或每股盈余产生实质性影响。

剥离这些产品线的决定是在对众多战略替代方案进行全面的评审和评估后作出的。这一决定与Covidien的战略相吻合，即：精简其产品组合，并将资源重新分配给该公司已经拥有或能够开发出全球竞争优势的发展更快、利润更高的业务部门。

关于COVIDIEN

Covidien是一家全球领先的健康保健产品公司，致力于为改善患者的用药效果提供创新的医疗解决方案，并通过在临床领域的领导地位及卓越表现创造价值。Covidien在三大业务领域制造和销售业界领先的产品线，并提供相应服务，这三大领域包括：医疗设备、医药产品和医疗用品。2009年，Covidien公司的营业收入高达107亿美元，公司在全球60多个国家拥有42,000多名员工，其产品销往140多个国家。更多有关我们业务的信息，请登录公司网站：www.covidien.com。

前瞻性陈述

本新闻稿中所包含的任何并非对历史事实进行描述的陈述均可能会构成《1995年美国私人证券诉讼改革法案》中所定义的前瞻性陈述。此处所包含的任何前瞻性陈述均基于公司管理层目前的信念和预期，但仍可能受到多种风险、不确定性及情况变化的影响，因而可能导致实际结果或公司行为与这些陈述中所明示或暗示的产生实质性差异。可能导致实际未来结果与当前预期产生实质性差异的因素包括但不限于：睡眠疗法交易可能无法完成或完成时间可能延后，能否有效引进并销售新产品或跟上技术发展步伐，少数大型公共和私人保险公司的偿付行为，客户、采购团体、第三方付款人及政府组织的成本控制努力，知识产权纠纷，复杂及高费用的监管，包括医疗保健欺诈和监管的滥用，制造或供应链出现问题或中断，商品成本的上升，产品召回或安全警告以及与Covidien公司或其产品有关的负面宣传，产品责任损失和其他诉讼责任(包括泰科公司遗留的相关诉讼)，一些业务或产品线的剥离，公司执行战略性收购、投资或与其他公司和企业联盟的能力，竞争，在美国以外地区经营业务的相关风险，外汇交易汇率或潜在环保责任。这些及其他因素在我们提交给美国证券交易委员会的文件中都进行了更加详细的界定和说明。除法律规定的要求外，公司不承担更新这些前瞻性陈述的义务。

免责声明：本公告之原文版本乃官方授权版本。译文仅供方便了解之用，烦请参照原文，原文版本乃唯一具法律效力之版本。

联系方式：

Covidien
Eric Kraus, 508-261-8305
通讯部高级副总裁
eric.kraus@covidien.com
或
Bruce Farmer, 508-452-4372
公关部副总裁
bruce.farmer@covidien.com
或
Coleman Lannum, CFA, 508-452-4343
投资者关系部副总裁
cole.lannum@covidien.com
或
Brian Nameth, 508-452-4363
投资者关系部总监
brian.nameth@covidien.com

 Covidien Announces Portfolio Management Activities

DUBLIN, Jun 01, 2010 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products, today announced a definitive agreement to sell its Sleep Therapy continuous positive airway pressure (CPAP) and Bi-level products to PH Invest, a privately held company located in Luxembourg.

PH Invest will acquire the CPAP and Bi-level products, including the Nancy, France manufacturing facility, as well as related commercial operations in Europe. Several products, which are sold under the GoodKnight(TM) and Sandman(TM) brands, are included in this agreement. The agreement excludes the sleep interface products sold and marketed under the brand names Adam(TM), Breeze(TM) and Dreamfit(TM), which will continue to be sold by Covidien. Financial terms of this transaction were not disclosed.

This transaction, which is subject to customary closing conditions, is expected to be completed in the next 90 days and is not expected to have a material effect on operating income or earnings per share for 2010 or 2011.

In addition, Covidien has completed the previously announced sale of its radiopharmacies in the United States to Triad Isotopes, Inc. of Orlando, FL. Financial terms of that transaction were not disclosed.

Covidien's radiopharmacy net sales were $91 million in the first six months of fiscal 2010. This transaction is not expected to have a material effect on Covidien's operating income or earnings per share for fiscal 2010 or 2011.

The decision to divest these product lines was made following a thorough review and evaluation of a number of strategic alternatives. The decision is consistent with Covidien's strategy to streamline its portfolio and reallocate resources to its faster-growing, higher-margin businesses, where the Company has, or can develop, a global competitive advantage.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2009 revenue of $10.7 billion, Covidien has 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

FORWARD-LOOKING STATEMENTS

Any statements contained in this communication that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or Company actions to differ materially from what is expressed or implied by these statements. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, the possibility that the sleep therapy transaction will not close or that the closing may be delayed, our ability to effectively introduce and market new products or keep pace with advances in technology, the reimbursement practices of a small number of large public and private insurers, cost-containment efforts of customers, purchasing groups, third-party payors and governmental organizations, intellectual property rights disputes, complex and costly regulation, including healthcare fraud and abuse regulations, manufacturing or supply chain problems or disruptions, rising commodity costs, recalls or safety alerts and negative publicity relating to Covidien or its products, product liability losses and other litigation liability, including legacy Tyco-related litigation, divestitures of some of our businesses or product lines, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, competition, risks associated with doing business outside of the United States, foreign currency exchange rates or potential environmental liabilities. These and other factors are identified and described in more detail in our filings with the SEC. We disclaim any obligation to update these forward-looking statements other than as required by law.

SOURCE: Covidien

Covidien
Eric Kraus, 508-261-8305
Senior Vice President
Communications
eric.kraus@covidien.com
or
Bruce Farmer, 508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Brian Nameth, 508-452-4363
Director
Investor Relations
brian.nameth@covidien.com